Imidazo[4,5-c]pyridine compound and method of antiviral treatment
    24.
    发明申请
    Imidazo[4,5-c]pyridine compound and method of antiviral treatment 审中-公开
    咪唑并[4,5-c]吡啶化合物和抗病毒治疗方法

    公开(公告)号:US20060252791A1

    公开(公告)日:2006-11-09

    申请号:US11316050

    申请日:2005-12-21

    IPC分类号: A61K31/4745 C07D471/02

    CPC分类号: C07D471/04

    摘要: The compound 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, together with the salts and solvates thereof. Also provided are compositions comprising this compound and pharmaceutically acceptable carriers, as well as the use of such compositions in the treatment or prophylaxis of viral infections.

    摘要翻译: 化合物5 - ((3-(2,4-三氟甲基苯基)异恶唑-5-基)甲基)-2-(2-氟苯基)-5H-咪唑并[4,5-c]吡啶与盐和溶剂合物 其中。 还提供了包含该化合物和药学上可接受的载体的组合物,以及这些组合物在治疗或预防病毒感染中的用途。

    Receptor specific atrial natriuretic peptides
    29.
    发明授权
    Receptor specific atrial natriuretic peptides 失效
    受体特异性心房利钠肽

    公开(公告)号:US5665704A

    公开(公告)日:1997-09-09

    申请号:US451240

    申请日:1995-05-25

    IPC分类号: A61K38/00 C07K14/58

    CPC分类号: C07K14/58 A61K38/00

    摘要: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

    摘要翻译: 含有各种取代,特别是G16R的人受体选择性心房利钠因子变体对人A受体显示相同的效力和结合亲和力,但对人清除或C-受体的亲和力降低。 这些ANF变体具有利钠,利尿和血管舒张活性,但具有增加的代谢稳定性,使其适合于治疗充血性心力衰竭,急性肾衰竭和肾性高血压。